20 and older, any sex, with Glaucoma or Ocular Hypertension. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change From Baseline in Intraocular PressurePrimary· Baseline and week 4,8,12,16,20,24,28,32,36,40,44,48,52
Change from baseline in intraocular pressure (IOP) following treatment with latanoprostene bunod 0.024% (instilled QD in the evening) with IOP assessed every 4 weeks from Week 4 to Week 52.
Week 4
Group
Value
95% CI
Latanoprostene Bunod
-4.30
± 2.746
Week 8
Group
Value
95% CI
Latanoprostene Bunod
-4.57
± 2.610
Week 12
Group
Value
95% CI
Latanoprostene Bunod
-4.76
± 2.846
Week 16
Group
Value
95% CI
Latanoprostene Bunod
-4.79
± 2.742
Week 20
Group
Value
95% CI
Latanoprostene Bunod
-4.94
± 2.707
Week 24
Group
Value
95% CI
Latanoprostene Bunod
-4.94
± 2.877
Week 28
Group
Value
95% CI
Latanoprostene Bunod
-4.93
± 2.703
Week 32
Group
Value
95% CI
Latanoprostene Bunod
-5.04
± 2.789
Clinical SafetyPrimary· 1 year
Ocular adverse events reported over one year of once daily dosing of latanoprostene bunod 0.024%. Below is the percentage of subjects with \>/=1 ocular AE Specifics of AEs are captured in the AE section.
Group
Value
95% CI
Latanoprostene Bunod
76
Adverse events — posted to ClinicalTrials.gov
Time frame: 1 year.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Latanoprostene Bunod
Serious: 5/130 (4%)
Deaths: —
Serious adverse events (6 terms)
Reaction
System
Latanoprostene Bunod
Stomach cancer
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
—
vestibular neuronitis
Infections and infestations
—
Car accident
Injury, poisoning and procedural complications
—
left tibia plateau fracture
Injury, poisoning and procedural complications
—
Lung Cancer
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
—
Lung ademocarcinoma
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
NCT07217678 — Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
· Phase 4
· recruiting
NCT07145073 — Repetitive Transcranial Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies
· NA
· recruiting
NCT07209410 — Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanopro
· Phase 4
· recruiting
Other Bausch & Lomb Incorporated trials
Trials by the same sponsor.
NCT07054606 — A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear
· Phase 4
· completed
NCT06803654 — A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Rel
· Phase 3
· completed
NCT06594185 — A Study to Evaluate Real World Outcomes of the enVista® Aspire (EA) and Aspire Toric (ETA) Intraocular Lens in Subjects
· NA
· completed
NCT06479148 — Clinical Evaluation of the Performance of the enVista® Aspire™ (EA) Lens
· NA
· terminated
NCT06333028 — A Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract Extraction
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bausch & Lomb Incorporated
Last refreshed: 26 July 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01895972.